Loading
NMS-03305293 is an experimental pill being studied to block a DNA-repair enzyme in cancer cells.
PARP1-selective, brain-penetrant inhibitor, also called NMS-293. The linked registry records distinguish recruiting, closed, and discontinued studies; those states do not establish comparative efficacy or approval. The monotherapy study NCT04182516 stopped after 52 actual participants because the sponsor shifted towards combinations, explicitly not because of emerging safety or efficacy concerns. Combination studies include temozolomide and topotecan.
PARP1-selective, brain-penetrant inhibitor, also called NMS-293. Connects to PARP.
1.NMS-03305293 slips into a pocket on PARP.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"NMS-03305293" OR ABSTRACT:"NMS-03305293" OR TITLE:"NMS-293" OR ABSTRACT:"NMS-293") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about NMS-03305293, not a curated reading list.
Shares PARP, Small-cell lung cancer.
Shares PARP, Ovarian cancer.
Shares PARP, Ovarian cancer.
Shares PARP, Ovarian cancer, Small-cell lung cancer.
Shares PARP, Ovarian cancer, Small-cell lung cancer.
Shares PARP, Ovarian cancer.
Shares PARP, Ovarian cancer.
Shares PARP, Ovarian cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/